Therefore, we propose that anti-β2-M Ab is a promising agent in aggressive prostate cancer bone metastatic patients and therefore combination treatment with the antibody and radiation will reduce tumor burden in such patients. The gene discussed is B2M; the disease is prostate carcinoma.